1. Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experienceTanja Mesti, Maja Ebert Moltara, Marko Boc, Martina Reberšek, Janja Ocvirk, 2015, izvirni znanstveni članek Povzetek: Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial. Patients and methods. The medical documentation of 19 adult patients with recurrent malignant gliomas was retrospectively reviewed. All patients received bevacizumab (10 mg/kg) and irinotecan (340 mg/m2 or 125 mg/m2) every two weeks. Patient clinical characteristics, drug toxicities, response rate, progression free survival (PFS) and overall survival (OS) were evaluated. Results. Between August 2008 and November 2011, 19 patients with recurrent malignant gliomas (median age 44.7, male 73.7%, WHO performance status 0%2) were treated with bevacizumab/irinotecan regimen. Thirteen patients had glioblastoma, 5 anaplastic astrocytoma and 1 anaplastic oligoastrocytoma. With exception of one patient, all patients had initially a standard therapy with primary resection followed by postoperative chemoradiotherapy. Radiological response was confirmed after 3 months in 9 patients (1 complete response, 8 partial responses), seven patients had stable disease and three patients have progressed. The median PFS was 6.8 months (95% confidence interval [CI]: 5.3-8.3) with six-month PFS rate 52.6%. The median OS was 7.7 months (95% CI: 6.6-8.7), while six-month and twelve-month survival rates were 68.4% and 31.6%, respectively. There were 16 cases of hematopoietic toxicity grade (G) 1-2. Non-hematopoietic toxicity was present in 14 cases, all G1-2, except for one patient with proteinuria G3. No grade 4 toxicities, no thromboembolic event and no intracranial hemorrhage were observed. Conclusions. In recurrent malignant gliomas combination of bevacizumab and irinotecan might be an active regimen with acceptable toxicity. Ključne besede: recurrent malignant glioma, systemic therapy, bevacizumab Objavljeno v DiRROS: 17.04.2024; Ogledov: 39; Prenosov: 5 Celotno besedilo (534,06 KB) |
2. Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer : a single institution retrospective analysisMartina Reberšek, Marko Boc, Petra Škerl, Jernej Benedik, Zvezdana Hlebanja, Neva Volk, Srdjan Novaković, Janja Ocvirk, 2011, izvirni znanstveni članek Ključne besede: rak (medicina), debelo črevo, danka, zdravljenje Objavljeno v DiRROS: 18.03.2024; Ogledov: 72; Prenosov: 27 Celotno besedilo (461,04 KB) |
3. Cisplatin-induced non-convulsive posterior reversible encephalopathy syndrome in a 41-year-old woman with metastatic malignant melanomaJanja Ocvirk, Marko Boc, Martina Reberšek, Tanja Roš-Opaškar, 2009, izvirni znanstveni članek Povzetek: Background. Cisplatin, a widely used antineoplastic agent usually induces peripheral neuropathy, but can rarely also complicate with encephalopathy, with or without seizures. Case report. We report a case of a young patient with metastatic malignant melanoma with signs and symptoms of cisplatin-induced non-convulsive posterior reversible encephalopaty syndrome. Within the days shortly after the first cycle of cisplatin based chemotherapy the patient suffered from nausea, vomitus, headache, severe pain at the site of sub-cutaneous metastases and confusion. She later experienced somnolence, cortical blindness and aphasia, but without epileptic seizures. Conclusions. Cisplatin is an effective chemotherapeutic drug but also very toxic one and physicians using it must also be aware of possible encephalopathy. Objavljeno v DiRROS: 08.03.2024; Ogledov: 111; Prenosov: 34 Celotno besedilo (343,74 KB) |
4. |
5. Electrochemotherapy with cisplatin of breast cancer tumor modules in a male patientMartina Reberšek, Tanja Čufer, Zvonimir Rudolf, Gregor Serša, 2000, izvirni znanstveni članek Povzetek: Background. The metastases of breast cancer in a male patient were treated with electrochemotherapy by intratumoral injection of cisplatin. Electrochemotherapy is chemotherapy with the subsequent local application of electric pulses to the tumor nodules in order to increase drug delivery into the cells. Case report. Cutaneous metastases of breast cancer were treated with the intratumoral administration of cisplatin and by 8 electric pulses (1300 V/cm) applied a minute later to each cutaneous metastasis. The treatmentresulted in complete response of two electrochemotherapy treated cutaneous metastases and partial response of the third metastasis. In cutaneous metastases treated with intratumoral administartion of cisplatin without electric pulses, only partial response was obtained. Conclusion. This study confirms that electrochemotherapy with cisplatin is effective in the treatment of breast cancer metastases, too, as it was already proved for electrochemotherapy with bleomycin. Objavljeno v DiRROS: 25.01.2024; Ogledov: 138; Prenosov: 35 Celotno besedilo (267,61 KB) |
6. |
7. Sistemsko zdravljenje metastatskega uvealnega melanomaMartina Reberšek, 2023, objavljeni znanstveni prispevek na konferenci Povzetek: Uvealni melanom spada med redke rake, predstavlja majhen odstotek vseh melanomov. Se razlikuje od kožnega melanoma, z nizkim tumorskim bremenom in 1-letnim preživetjem v polovici bolnikov z metastatsko boleznijo. Sistemsko zdravljenje metastatske bolezni je malo učinkovito, v primeru prisotnega genotipa HLA-A*02:01 pa je zdravljenje s tebentafuspom izboljšalo prognozo teh bolnikov. Ključne besede: rak kože, melanom, sistemsko zdravljenje Objavljeno v DiRROS: 18.05.2023; Ogledov: 304; Prenosov: 125 Celotno besedilo (245,55 KB) Gradivo ima več datotek! Več... |
8. Sistemsko dopolnilno zdravljenje kožnega melanoma : imunoterapija in tarčna terapijaMirjana Amon, Martina Reberšek, 2023, objavljeni znanstveni prispevek na konferenci Povzetek: Melanom je maligni tumor melanocitov. Melanociti so celice, ki proizvajajo pigment melanin in izhajajo iz celic nevralnega grebena. Večina melanomov nastane v koži, sicer lahko nastanejo na vseh lokalizacijah, kjer migrirajo celice nevralnega grebena, kot so na primer sluznice, okularni uvealni trakt ali CŽS. Manj kot 5% kožnih rakov so maligni melanomi, ki sodijo v skupino kožnih rakov z najslabšo prognozo. Zaradi svoje agresivne narave ima najvišjo stopnjo smrtnosti med vsemi kožnimi raki (80%). Zgodnje odkritje melanoma in njegovo pravočasno zdravljenje pomembno vplivata na prognozo same bolezni. Ključne besede: rak kože, melanom, sistemsko zdravljenje Objavljeno v DiRROS: 17.05.2023; Ogledov: 283; Prenosov: 108 Celotno besedilo (321,50 KB) Gradivo ima več datotek! Več... |
9. Novosti v dopolnilnem sistemskem zdravljenju kožnega melanomaMartina Reberšek, 2023, objavljeni znanstveni prispevek na konferenci Povzetek: Bolniki z operiranim stadijem III in stadijem IV, brez ostanka bolezni, kot tudi z visoko rizičnim stadijem II, imajo visoko tveganje za ponovitev bolezni. V zadnjem desetletju se je prognoza bolnikov z metastatskim kožnim melanomom v zadnjem desetletju zaradi sistemskega zdravljenja močno izboljšala z daljšimi preživetji, so se tako po zaključenih kliničnih raziskavah faze III v zadnjih letih izboljšali tudi rezultati zdravljenja in prognoza z manjšo verjetnostjo ponovitve bolezni tudi pri bolnikih z operiranim kožnim melanomom v stadijih III in IV brez ostanka bolezni z uvedbo imunoterapije z zaviralci imunskih kontrolnih točk in tarčne terapije v primeru prisotne BRAF mutacije v adjuvantnem zdravljenju, kot tudi pri bolnikih z visoko rizičnim stadijem II z imunoterapijo z zaviralcem imunskih kontrolnih točk. Ključne besede: rak kože, melanom, sistemsko zdravljenje Objavljeno v DiRROS: 17.05.2023; Ogledov: 248; Prenosov: 101 Celotno besedilo (90,37 KB) Gradivo ima več datotek! Več... |
10. Mikrobiom in imunoterapijaMartina Reberšek, 2023, objavljeni znanstveni prispevek na konferenci Povzetek: Črevesna mikrobiota ima ključno vlogo tako pri vzdrževanju človekovega zdravja kot razvoju boleznih, predvsem kroničnih in tudi raka. Imunoterapija z zaviralci imunskih kontrolnih točk je učinkovito pri različnih rakih pri različnih rakih, kot so melanom, pljučni rak, rak ledvic, vendar le v eni tretjini bolnikov. Modulacija črevesne mikrobiote s ustrezno prehrano, probiotiki s prebiotiki, kot tudi z genetsko modifikacijo mikrobiote in fekalno transplantacijo črevesne mikrobiote poveča protitumorski imunski odziv in s tem učinkovitost imunoterapije z zaviralci imunskih kontrolnih točk. Ključne besede: imunoterapija, onkologija, onkološko zdravljenje Objavljeno v DiRROS: 16.02.2023; Ogledov: 398; Prenosov: 204 Celotno besedilo (16,12 MB) Gradivo ima več datotek! Več... |